MedPath

Study Evaluating Pantoprazole in Adolescents With GERD

Phase 3
Completed
Conditions
Gastroesophageal Reflux
Registration Number
NCT00367614
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

The purpose of this study is characterize the PK profile of single and multiple doses of pantoprazole in adolescents aged 12 to 16 years with Gastroesophageal Reflux Disease (GERD).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • 12-16 years old
  • clinical diagnosis of GERD
  • ability to swallow tablets
Exclusion Criteria
  • GI or malabsorption disorders
  • chronic use of warfarin
  • positive pregnancy test

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Characterization of the PK profile of single and multiple doses of pantoprazole.
Secondary Outcome Measures
NameTimeMethod
Assess the safety and tolerability of pantoprazole.
© Copyright 2025. All Rights Reserved by MedPath